This is one of our favorite Peptides here at Star Bio, it’s worth the cost

Tesamorelin: Research Insights Into Gut Fat and Athletic Physiques

Athletes and bodybuilders have long been interested in how hormones influence muscle growth, fat loss, and recovery. While much attention has been given to growth hormone (GH) itself, research peptides like tesamorelin provide a unique way to study how stimulating natural GH release affects body composition.

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH). In studies, it has consistently shown an ability to increase GH and IGF-1 in a more physiological, pulsatile manner. But what makes tesamorelin stand out isn’t just higher hormone levels — it’s the documented reduction of visceral fat, one of the hardest and most stubborn types of fat to shift.

What the studies show

Clinical trials originally explored tesamorelin in people with abdominal fat linked to metabolic changes. The findings were clear: tesamorelin reduced visceral adipose tissue (VAT) significantly, without major losses in lean body mass.

Falutz et al. (2007): In a 26-week placebo-controlled trial, tesamorelin reduced visceral fat by about 15% on average, while subcutaneous fat (under the skin) was less affected. Importantly, IGF-1 levels rose in a controlled and sustained way, mimicking a healthier GH rhythm.

Falutz et al. (2010, NEJM): In a longer 52-week trial, reductions in VAT were maintained over time, with some improvements in triglycerides and cholesterol markers. Lean mass was preserved, which sets tesamorelin apart from many diet-driven fat-loss strategies that also strip muscle.

For athletes, this pattern is especially valuable. The research suggests that midsection fat can be reduced while muscle is spared, creating a leaner, harder look without compromising strength.

Why visceral fat matters for athletes

Most athletes focus on subcutaneous fat because it’s what you see in the mirror. But visceral fat — the deep abdominal fat packed around organs — is different. It’s linked with slower recovery, systemic inflammation, and metabolic drag.

By targeting visceral fat, tesamorelin creates an environment that may support:

A leaner midsection, improving the overall aesthetic of the physique

Reduced metabolic stress, helping recovery from intense training

Better endurance in long training blocks due to improved metabolic balance

This explains why tesamorelin has become an intriguing focus for those studying physique development, strength performance, and recovery.

Bodybuilders, CrossFitters, and strength athletes

Different sports place different demands on the body, but the benefits of reduced visceral fat extend across them all.

Bodybuilders: Off-season phases often lead to increases in belly fat even with clean eating. Tesamorelin research suggests a way to maintain leanness around the core while adding size.

Strength athletes: Carrying excess visceral fat doesn’t add to lifting totals — it just slows recovery. Research into tesamorelin shows lean tissue is spared while the “bad fat” is reduced.

CrossFitters and hybrid athletes: High-volume, high-intensity training creates metabolic strain. Lower visceral fat may mean improved resilience during long sessions and faster bounce-back between workouts.

A unique angle compared to other peptides

While other peptides can elevate GH or improve recovery, tesamorelin is the only one with large-scale, peer-reviewed human trials showing selective visceral fat loss. This gives it a unique place in the research landscape. Instead of just boosting hormone levels, it demonstrates a measurable body composition shift that many athletes strive for.

The bottom line

From a scientific standpoint, tesamorelin is a reliable tool for raising GH and IGF-1 in a natural rhythm. But what makes it especially interesting for the sports and bodybuilding community is its proven impact on visceral fat reduction without muscle loss. For researchers studying body composition, recovery, and metabolic health in athletes, it offers one of the most compelling models available.

References

Falutz J et al. “Effects of tesamorelin, a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial.” J Clin Endocrinol Metab. 2007;92(9):3444–3455. https://pubmed.ncbi.nlm.nih.gov/17595259

Falutz J et al. “Metabolic effects of a growth hormone–releasing factor in patients with HIV.” N Engl J Med. 2010;362:2075–2085. https://pubmed.ncbi.nlm.nih.gov/20519679